^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GPC3-CAR and IL15 plus IL21

i
Other names: CARE T cells, GPC3-CAR and IL15 plus IL21, 15.21.GPC3-CAR T cells, interleukin-15 and -21 armored glypican-3-specific chimeric antigen receptor expressing autologous T cells
Associations
Company:
Baylor College of Medicine
Drug class:
GPC-3-targeted CAR-T immunotherapy, IL-15-targeted CAR-T immunotherapy, IL-21-targeted CAR-T immunotherapy
Associations
3ms
Enrollment open
|
GPC3 (Glypican 3)
|
cyclophosphamide • fludarabine IV • GPC3-CAR and IL15 plus IL21
10ms
New P1 trial • CAR T-Cell Therapy
|
GPC3-CAR and IL15 plus IL21
almost3years
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jul 2040 --> Jul 2041 | Initiation date: Jul 2022 --> Jul 2023 | Trial primary completion date: Aug 2025 --> Aug 2026
Trial completion date • Trial initiation date • Trial primary completion date
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • GPC3-CAR and IL15 plus IL21
almost4years
Clinical • New P1 trial
|
GPC3 (Glypican 3)
|
GPC3 positive
|
fludarabine IV • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous